Redeye provides a research update on Faron Pharmaceuticals following the outcome of the company’s recent share issue and clinical progress with lead candidate bexmarilimab. Bolstered by promising interim results from the BEXMAB study, we raise our LoA for bexmarilimab. Having adjusted for the share issue, we revise our valuation with an updated base case of EUR2 (5) per share.